Cogent Biosciences (COGT) Change in Accured Expenses (2017 - 2026)

Cogent Biosciences' Change in Accured Expenses history runs 10 years deep, the most recent figure standing at $29000.0 for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 480.0% year-over-year to $29000.0; the TTM figure through Mar 2026 stood at $10.7 million (up 59.26% YoY), while the FY2025 annual figure was $10.7 million, changed N/A from the prior year.
• Change in Accured Expenses was $29000.0 for Q1 2026 at Cogent Biosciences, down from $9.1 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $10.1 million in Q2 2024 to a low of -$10.3 million in Q4 2024.
• Historically, Change in Accured Expenses has averaged $1.7 million across 5 years, with a median of $2.6 million in 2022.
• The sharpest annual moves came in 2023 and 2026: Change in Accured Expenses plunged 1384.92% in 2023, then jumped 480.0% in 2026.
• A 5-year view of Change in Accured Expenses shows it stood at $3.8 million in 2022, then sank by 30.93% to $2.6 million in 2023, then plunged by 491.74% to -$10.3 million in 2024, then soared by 188.39% to $9.1 million in 2025, then plunged by 99.68% to $29000.0 in 2026.
• The last three Change in Accured Expenses figures came in at $29000.0 (Q1 2026), $9.1 million (Q4 2025), and $4.6 million (Q3 2025), per Business Quant data.